Biotech

All Articles

Amgen reports very first phase 3 win for $400M eczema medicine

.Amgen has discussed (PDF) the initial stage 3 data on its own $400 thousand eczema medicine, connec...

Biogen, UCB record period 3 lupus gain after falling short earlier test

.Biogen and also UCB's gamble on developing in to stage 3 astride an unsuccessful study tries to hav...

Aptadir hopes brand new RNA preventions can reverse difficult cancers

.Italian biotech Aptadir Therapies has introduced with the commitment that its pipeline of preclinic...

Wave surfs DMD results to regulators' doors, sending stockpile

.Surge Lifestyle Sciences has actually satisfied its objective in a Duchenne muscular dystrophy (DMD...

Sanofi tweezes brand-new CSO coming from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, occupyin...

Achilles drops tissue therapy plan, bandages for discharges after missing out on 'commercial stability' objectives

.Achilles Therapies has shreded its approach. The British biotech is actually stopping work on its c...

Aligos advertises period 2 MASH gain, lowering liver excess fat as much as 46%

.Aligos Therapeutics is actually declaring a midstage succeed in metabolic-dysfunction linked steato...

Basilea ratings $268M BARDA financing for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job developing new antifungals has acquired a substantial boost coming from...

Capricor markets Europe civil liberties to late-stage DMD therapy for $35M

.Possessing presently gathered up the USA civil liberties to Capricor Therapies' late-stage Duchenne...

FDA junks adcomm for Applied's rare ailment medication

.After pushing the decision date for Applied Therapies' metabolic condition drug govorestat, the FDA...